SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 2004; 23: 31944.
  • 2
    Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother 2002; 16: 928.
  • 3
    Hogan DB. Which older patients are competent to drive? Approaches to office-based assessment. Can Fam Physician 2005; 51: 3628.
  • 4
    Drummer OH. The role of drugs in road safety. Aust Prescr 2008; 31: 335.
  • 5
    Augsburger M, Rivier L. Drugs and alcohol among suspected impaired drivers in Canton de Vaud (Switzerland). Forensic Sci Int 1997; 85: 95104.
  • 6
    Council Directive 83/570/EEC of 26 October 1983 amending Directives 65/65/EEC, 75/318/EEC and 75/319/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products. OJL 332, 28.11.1983, pp. 110. Available at http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31983L0570:EN:HTML (Accessed July 2011).
  • 7
    Alvarez FJ, del Rio MC. Drugs and driving. Lancet 1994; 344: 282.
  • 8
    de Gier JJ, Alvarez FJ, Mercier-Guyon C, Verstraete AG. Prescribing and dispensing guidelines for medicinal drugs affecting driving performance. In: Drugs, Driving and Traffic Safety, eds Verster JC, Pandi-Perumal SR, Ramaekers JG, de Gier JJ. Basel: Birkaeuser Verlag AG, 2009; 12134.
  • 9
    Álvarez FJ, Del Río MC. Medicinal drugs and driving: from research to clinical practice. Trends Pharmacol Sci 2002; 23: 4415.
  • 10
    European Commission. Enterprise and Industry Directorate-General. A guideline on summary of product characteristics (SmPC) 2009 [online]. Available at http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf and http://ec.europa.eu/health/documents/eudralex/vol-2/index_en.htm (Accessed July 2011).
  • 11
    de Gier JJ. Drugs and driving research: application of results by drug regulatory authorities. Hum Psychopharmacol Clin Exp 1998; 13: S133S136.
  • 12
    Pil K, Raes E, van den Neste T, Goessaert AS, Veramme J, Verstraete AG. Review of existing classification efforts (DRUID Deliverable 4.1.1.). 2008. Available at http://www.druid-project.eu/cln_007/nn_107534/Druid/EN/deliverales-list/deliverables-list-node.html?__nnn=true (Accessed July 2011).
  • 13
    Wolschrijn H, de Gier JJ, de Smet PAGM. Drugs and driving: a new categorization system for drugs affecting psychomotor performance. Institute for Drugs, Safety and Behavior, University of Limburg, the Netherlands. 1991. Tech Report.
  • 14
    Toxicological Society of Belgium and Luxembourg asbl. Influence des médicaments sur les capacités de conduire. Bruxelles: Toxicological Society of Belgium and Luxembourg asbl, 1999.
  • 15
    Del Río MC, Alvarez FJ, González-Luque JC. Guía De Prescripción Farmacológica Y Seguridad Vial [The Pharmaceutical Prescription Guidelines and Road Safety], 2nd edn. Madrid: Dirección General de Tráfico, 2002.
  • 16
    Agency for Medicinal Products and Medical Devices of the Republic of Slovenia. Rules on labelling of medicinal products and on the packaging leaflet. Official Journal of the Republic of Slovenia, No. 54/06 and the Medicinal Products Act (Official Journal of the Republic of Slovenia, No. 31/06). 2006.
  • 17
    ICADTS Working Group on Prescribing and Dispensing Guidelines for Medicinal Drugs Affecting Driving Performance. Prescribing and Dispensing Guidelines for Medicinal Drugs Affecting Driving Performance. Utrecht: International Council on Alcohol, Drugs and Traffic Safety, 2001. Available at http://www.icadts.nl/medicinal.html (Accessed July 2011).
  • 18
    Ministère de la Santé et des Solidarités. Direction Generale de la Santé. Arrêté du 18 Juillet 2005 pris pour l'application de l'article R.5121-139 du code de la santé publique et relative à l'opposition d'un pictogramme sur le conditionnement extérieur de certain médicaments et produits. Journal Officiel de la République Française. Août 2005 (SAN/P0522726A).
  • 19
    Real Decreto 1345/2007, de 11 de octubre, por el que se regula el procedimiento de autorización, registro y condiciones de dispensación de los medicamentos de uso humano fabricados industrialmente. BOE de 7 de Noviembre de 2007, pp: 4565245698.
  • 20
    Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (KNMP). Contra-indicatie Verkeersdeelname. Contra-indication ‘Participation in traffic’ (in Dutch). Instituut voor Verantwoord Medicijngebruik 2008 [online]. Available at http://www.geneesmiddeleninhetverkeer.nl (Accessed July 2011).
  • 21
    Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) – Médicaments et conduite automobile – Mise au point. 6/04/2009. Available at http://www.afssaps.fr/Infos-de-securite/Recommandations/Medicaments-et-conduite-automobile-Mise-au-point/(language)/fre-FR (Accessed July 2011).
  • 22
    Agencia Española de Medicamentos y Productos Sanitarios. Medicamentos y Conduccion. Available at http://www.aemps.gob.es/industria/etiquetado/conduccion/home.htm (Accessed July 2011).
  • 23
    Driving Under the Influence of Drugs, Alcohol and Medicines – DRUID. Available at http://www.druid-project.eu/ (Accessed July 2011).
  • 24
    Gómez-Talegón T, Fierro I, Del Río MC, Álvarez FJ. Establishment of framework for classification/categorisation and labelling of medicinal drugs and driving. Deliverable 4.3.1, 2011. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Available at http://www.druid-project.eu/ (Accessed July 2011).
  • 25
    Collaborating WHO Centre for Drug Statistics Methodology. ATC/DDD index. Available at http://www.whocc.no/atc_ddd_index/ (Accessed July 2011).
  • 26
    Medicines and Healthcare Products Regulatory Agency- MHRA. Available at http://www.mhra.gov.uk/index.htm (Accessed July 2011).
  • 27
    Electronic Medicines Compendium – eMC. Available at http://www.medicines.org.uk/EMC/default.aspx (Accessed July 2011).
  • 28
    Irish Medicines Board – IMB. Available at http://www.imb.ie/ (Accessed July 2011).
  • 29
    European Medicines Agency – EMA. Human Medicines. European public assessment report. Available at http://www.ema.europa.eu/ema/index.jsp (Accessed July 2011).
  • 30
    Talbot J, Stephens MDB. Clinical trials: – collection of safety data and establishing the adverse drug reaction profile. In: Stephens' Detection of New Adverse Drug Reactions, 5th edn. eds Talbot J, Stephens MDB. Chichester: John Wiley and Sons, Ltd, 2004; 167242.
  • 31
    de Gier JJ, Ravera S, Monteiro SP, Álvarez FJ. 2011): Establishment of criteria for a European categorisation system for medicinal drugs and driving. Deliverable 4.2.1, 2011. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Available at http://www.druid-project.eu/ (Accessed July 2011).
  • 32
    EMA. Pharmacovigilance Working Party (PhVWP). Monthly report Issue number: 1106. June 2011 plenary meeting. EMA/CHMP/PhVWP/486894/2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/06/WC500108098.pdf (Accessed October 2011).